New York City to Pursue Rat Contraception Pilot Program

Rhea-AI Summary

SenesTech, Inc. (Nasdaq: SNES), the leader in rodent birth control, announces that the New York City Council has approved a bill to implement a rat contraception pilot program. The bill, Int. No. 736-A, requires the Department of Health and Mental Hygiene (DOHMH) to launch the program within 180 days, in collaboration with the Department of Sanitation (DSNY) and a rodent control expert.

The program will run for at least 12 months in two rat mitigation zones and a comparable area, focusing on residential buildings with waste in containers. SenesTech is currently the only manufacturer of EPA-approved rat contraceptives. The company's President and CEO, Joel Fruendt, expressed readiness to support New York City's pilot program with their product lines ContraPest® and Evolve™.

Positive

• SenesTech is the only manufacturer of EPA-approved rat contraceptives
• New York City Council approved a bill for rat contraception pilot program
• Potential for increased product demand in a major urban market

Negative

• None.

Insights

Environmental Policy Analyst

This development marks a significant shift in New York City's approach to rat control, moving from traditional extermination methods to a more sustainable, long-term solution. The pilot program's approval demonstrates a growing recognition of innovative pest management strategies in urban environments. SenesTech's unique position as the sole provider of EPA-approved rat contraceptives gives them a substantial competitive advantage in this emerging market.

The 12-month pilot in two rat mitigation zones will provide important data on the effectiveness of contraceptive methods in dense urban areas. If successful, this could lead to widespread adoption across New York City and potentially other major urban centers, opening up a significant market opportunity for SenesTech. However, investors should note that the pilot's success is not guaranteed and the company's performance may be heavily influenced by the program's outcomes.

Market Research Analyst

SenesTech's potential involvement in New York City's rat contraception program represents a major market opportunity. With a micro-cap of just $2.47 million, securing a contract with America's largest city could be transformative for the company's financials. The pilot program's success could lead to expanded use across New York's five boroughs and set a precedent for other major cities grappling with rat populations.

Investors should consider the scalability of SenesTech's products and their potential for adoption in other urban markets. However, it's important to balance this opportunity against the company's current financial position and ability to meet potential increased demand. The stock may see increased volatility as the market reacts to updates on the pilot program's progress and any hints of broader adoption.

PHOENIX, Oct. 8, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), the leader in birth control to manage rodent pest populations, today announces that the New York City Council has approved a bill to implement a rat contraception pilot program. From the bill, the term "rat contraceptive" means an agent for the reduction of reproductive capacity in rats that is approved for such use by the United States Environment Protection Agency. SenesTech is currently the only manufacturer of products that meet this requirement.

This bill, Int. No. 736-A, mandates the Department of Health and Mental Hygiene (DOHMH), in collaboration with the Department of Sanitation (DSNY) and a rodent control expert, to launch a pilot program deploying rat contraceptives within 180 days of enactment.

The program will run for at least 12 months in two rat mitigation zones and a comparable area, focusing on residential buildings with waste in containers. DOHMH must conduct monthly inspections, tracking rat activity, and report findings to the Mayor and City Council after the pilot period.

"SenesTech has two product lines on the market today, ContraPest® and Evolve™, that have shown efficacy and safety in deployments throughout the United States and around the globe. We are the provider of Rat Birth Control™. We look forward to supporting New York City in their pilot program," said Joel Fruendt, SenesTech's President and CEO.

About SenesTech, Inc.

We are committed to improving the health of the world by humanely managing animal pest populations through our expertise in fertility control. We are the inventors of Evolve™ Rat and Evolve™ Mouse, EPA-designated minimum risk contraceptives for rodents which reflect our mission to provide products that are proactive, safe and sustainable. Evolve fits seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. We strive for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable.

For more information visit https://senestech.com/

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, our expectation that the New York program will run for at least 12 months in two rat mitigation zones and a comparable area, focusing on residential buildings with waste in containers. Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the successful commercialization of our products, market acceptance of our products, our financial performance, including our ability to fund operations, our ability to maintain compliance with Nasdaq's continued listing requirements, regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:   
Investors:
Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC
602-889-9700, senestech@lythampartners.com

Media and Marketing Contact:
Rochelle Paulet, Director of Marketing, SenesTech, Inc.
928-779-4143 x814, rochelle.paulet@senestech.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/new-york-city-to-pursue-rat-contraception-pilot-program-302269011.html

SOURCE SenesTech, Inc.

FAQ

What is the ticker symbol for SenesTech?

SenesTech's ticker symbol is SNES, listed on the Nasdaq stock exchange.

What products does SenesTech offer for rat birth control?

SenesTech offers two product lines for rat birth control: ContraPest® and Evolve™.

When will New York City's rat contraception pilot program begin?

The pilot program is mandated to begin within 180 days of the bill's enactment.

How long will New York City's rat contraception pilot program last?

The pilot program will run for at least 12 months in selected rat mitigation zones.